GSK plc (GLAXF)

Market Cap	73.73B
Revenue (ttm)	39.28B
Net Income (ttm)	3.22B
Shares Out	n/a
EPS (ttm)	0.78
PE Ratio	22.87
Forward PE	n/a
Dividend	0.77 (4.25%)
Ex-Dividend Date	Feb 20, 2025

Volume	80
Average Volume	2,325
Open	18.50
Previous Close	18.22
Day's Range	18.22 - 18.50
52-Week Range	15.68 - 23.00
Beta	0.34
RSI	54.55
Earnings Date	Jan 31, 2025

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1715
• Employees: 70,212
• Stock Exchange: OTCMKTS
• Ticker Symbol: GLAXF

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP